NOW in Clinical Trials

Drugs that Reprogram Tumor Cells Introduce New Options for Blood Cancer Patients

ewc_TempleFC(2)0220150264-revA growing body of evidence supports the idea that epigenetic changes, which affect gene expression without altering the DNA sequence, play an important role in the initiation and progression of cancer. Because epigenetic therapies restore normal gene activity rather than kill cancer cells, they could be an attractive alternative for patients who cannot tolerate traditional chemotherapy. Continue Reading »

Trial to Evaluate Antibody-Drug Conjugate in Treating Metastatic Colorectal Cancer

THE TOPLINE Early results from a Phase I trial indicate that the antibody-drug conjugate IMMU-130 is safe and tolerable in treating relapsed metastatic colorectal cancers Investigators believe IMMU-130 may be more potent than the traditional treatment, as it binds directly to cancer cells Fox Chase medical oncologist Efrat Dotan, MD, is spearheading a Phase I clinical trial of IMMU-130, an antibody-drug conjugate, studying its efficacy and safety for use against metastatic colorectal cancers (mCRC) that have relapsed. “This is a novel treatment approach using an antibody-drug conjugate to deliver the treatment directly into the cancer cell and limit toxicity to healthy … Continue Reading »

Comments Off
A Kaplan-Meier plot comparing survival in cohorts of SCCHN patients with high and normal 
expression of Aurora kinase A, based on data from The Cancer Genome Atlas. Inhibiting the activity of Aurora kinase A is expected to improve survival for patients with elevated levels of Aurora kinase A.

Trials Explore a Synergistic Therapeutic Combination for Head and Neck, Lung Cancer

Epidermal growth factor receptors (EGFRs) are proven to be effective molecular targets for anti-cancer drugs, but what happens when EGFRs are targeted in conjunction with a lesser-studied enzyme — Aurora kinase A? Clinical trials underway at Fox Chase are exploring the effectiveness of this “two-hit” therapeutic approach in head and neck cancer as well as lung cancer. Continue Reading »

Comments Off
Above, ligand-dependent activation of HER3 and its subsequent dimerization with HER2 leads to potent activation of the PI3K/Akt pathway, a signaling cascade that plays essential roles in regulating cellular homeostasis. Inappropriate signaling through the HER2/HER3 heterodimer is linked to the formation and progression of a number of cancers, including gastric and breast cancers. MM-111, an anti- HER2/anti-HER3 bispecific antibody, blocks signaling through this critical receptor pair and inhibits the growth of HER2/HER3-driven cancer cells.

Drug Developed at Fox Chase Holds Promise for Gastroesophageal Cancer

A first-of-its-kind drug that emerged from research at Fox Chase Cancer Center is now moving into an important new area: gastroesophageal cancer. “This is a drug that could provide new therapeutic options in a disease that doesn’t have many,” says medical oncologist Crystal Denlinger, MD, who is leading a worldwide study to test the compound’s effectiveness in cancers of the stomach and esophagus. Continue Reading »

Comments Off

Fox Chase Offers Robust Selection of Phase I and First-in-Human Compound Trials

Fox Chase is home to a highly active Phase I clinical trial program, which enrolls 150 to 200 patients into Phase I oncology trials annually. The program is bolstered by Fox Chase’s Protocol Support Laboratory, one of the only laboratories in the country dedicated specifically to fulfilling the biospecimen-based research objectives of protocols for Institutional Review Board-approved clinical trials and investigational studies. The Center’s robust portfolio of Phase I trials includes about 15 trials of first-in-human compounds in any given year. “We have a lot of physicians who have an interest in early clinical drug development with the intent of finding … Continue Reading »

Comments Off
Next Page »